Due to the high cost and significant side effects of these medications, many studies show that more than half of patients have stopped them by the 12th month
Market Expansion & Competition Rival GLP-1 pills are in late-stage development, including Eli Lillys orforglipron , which could be approved in 2026
J., Mezquita-Raya, P., Carretero-Gmez, J., Castro, A., Cebrin-Cuenca, A., de Torres-Snchez, A., Garca-de-Lucas, M
Semaglutide trials reported 24-29% constipation rates while tirzepatide trials showed 12-27%
GLP-1 injections are a powerful aid in medical weight loss, providing individuals with an effective way to manage appetite and promote healthy weight loss
Melandri D, Zlatareva I, Chaleil RAG, Dart RJ, Chancellor A, Nussbaumer O, et al